Funding round-up: Hemispherian, Alan, Engimmune Therapeutics, Xinvento, STENTiT

The Netherlands: STENTiT, an emerging medical device company bringing a novel class of regenerative endovascular implants for the treatment of cardiovascular diseases, has closed a €1.8m (US$1.9m) seed investment round. The investment was made by the Dutch investors NextGen Ventures, Brabant Development Agency (BOM) and the Ten Cate Investment Company. The funding facilitates further pre-clinical…

You must be a HMI Subscriber to view this content.

Subscribe Now »